In this study we found that emodin reversed the gemcitabine resistance effect in pancreatic cancer, the action might be associating with down-regulation of NF-κB expression, and lowering the expression of P-gp and Bcl-2, increasing Bax expression. This evidence concerns the gene BCL2 and familial pancreatic carcinoma.